In today’s Pharmaceutical Executive Daily, we explore how AI is disrupting higher education and career pathways, AllRock ...

Novo Nordisk's shares rise as Phase III trial shows its oral Wegovy pill achieves significant weight loss, offering a new ...

Former CDC director Susan Monarez raises alarms about potential changes to childhood vaccine schedules, warning of increased ...

One of the biggest barriers to AI scaling is the traditional divide between business and IT functions. Siloed approaches ...

Roche strengthens its pipeline by acquiring 89bio and its promising MASH treatment, Pegozafermin, enhancing options for ...

GSK plans a $30 billion investment in US R&D and manufacturing, including $1.2 billion for advanced facilities and AI ...

Rob DeWig, Vice President of Healthcare Sales, Inmar, touches on the impact of Inmar and Premier's expanded agreement on the ...

Eli Lilly's Orforglipron shows superior results in glycemic control and weight loss compared to oral semaglutide in recent ...

As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately ...

FDA warns major pharmaceutical companies to improve transparency in drug advertising, addressing misleading claims and ...

Novo Nordisk's Rybelsus gains EU approval for cardiovascular benefits, enhancing treatment options for type 2 diabetes and ...

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s ...